

Chemical Safety assessment scheme



CONTENTS

- 1. ITS & Non-Testing (NT) data
- 2. Existing Guidance & Tools for generating NT data
- 3. Our experience
- 4. Developments for generating NT data
- 5. Exposure-based Waiving
- 6. Final Conclusions



1. ITS & Non-testing data

CSA steps (Annex VI)

- 1. Gather and share available information
- 2. Consider information needs
- 3. Identify information gaps
- 4. Generate new data / propose testing strategy



ITS:

"Efficient Information Gathering Strategy"

Step 1: Gather all available Testing and Non-Testing information



All available Testing and Non-Testing information

Human data



In vitro





Non-Testing information

(Q)SAR models



Grouping & read across

Exposure





General rules for adaptation of Standard (test) Requirements

Annex XI

- 1. Testing does not appear scientifically necessary
 - Use of existing data: PC, non-GLP etc, Historical human data
 - Weight of evidence
 - In vitro methods
 - Quantitative or Qualitative Structure Activity Relationships ((Q)SAR)
 - Grouping of substances and read-across approach
- 2. Testing is technically not possible
- 3. Substance-tailored exposure-driven testing



ITS: Information Gathering Strategy

Step 1: Gather all available Testing and Non-Testing information

If not sufficient (for C&L and RA) (Is Testing technically possible?)

Step 2: Is Exposure-Based Waiving an option?

Step 3: Perform / Propose Testing as last resort!!

If not possible

Testing in REACH very last resort: (a.o. in *art*.13, 25 & in Annex XI)

When assessing hazards





EBW 'opties': Als geen NT data, dan is er ook geen category-specific TTC afleidbaar.... en vervallen we dus naar de heel lage Munro of evt. Cramer TTC...



The current situation on available testing data

for about 30.000 (?!) REACH chemicals > 1 tpa



Allanou, Hansen and van Der Bilt, 1999

The current situation on available testing data

for about 30.000 (?!) REACH chemicals > 1 tpa



Potential Impact of NT data

HPV Challenge Program (US.EPA, 2004)

Endpoint data sources



Percent



Expected savings of NT in ITS under REACH

Van der Jagt et al., 2004⇒ Testing costs:€ 800-1130 million⇒ Number of animals:1.3-1.9 million

EUR report, 2005 (http://ecb.jrc.it)
⇒ Testing costs: € 1.500 million
⇒ Number of animals: 2.6 million



Estimated test animal need under REACH

(van der Jagt et al., 2004)





15

2. Existing Guidance & Tools for generating NT data





AHJA

Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals



May 2008

Guidance for the implementation of REACH



17 NT - ITS, Japan 09

Definitions

Structure Activity Relationship (SAR)

a qualitative relationship that relates a (sub)structure to the presence or absence of a property or activity of interest

Quantitative Structure Activity Relationship (QSAR)

a mathematical model relating one or more quantitative parameters derived from chemical structure to a quantitative measure of a property or activity of interest



Definitions (2)

category approach & *analogue approach* describe techniques for grouping chemicals

read-across

a technique of filling data gaps in either approach



19 NT - ITS, Japan 09

Definitions (3)

chemical category

a group of chemicals whose properties

i.e. phys-chem, human health and/or environmental toxicological and/or environmental fate

are likely to be similar or follow a regular pattern

as a result of structural similarity

In principle, the number of members generally present enables the detection of trends across endpoints (and robustness of conclusions)



Definitions (4)

analogue approach

a *limited* number of chemicals whose properties

i.e. phys-chem, human health and/or environmental toxicological and/or environmental fate

are likely to be similar

as a result of structural similarity

In principle, the *limited* number of chemicals do not allow identification of trends in these properties

















How identify category members or analogues in Step 1?

ChemID (*Plus Advanced*) AIM SciFinder OECD QSAR Toolbox DSSTox a.o.



How identify category members or analogues in Step 1?

By applying similarity principles:

- common functional group(s) related to a specific activity (e.g. aldehyde, epoxide, ester, specific metal ion)
- the likelihood of common precursors and/or breakdown products
- an incremental and constant change across the category (e.g. a chainlength category with differences in methylene groups)
- common constituents or chemical classes, similar carbon range numbers (UVCB substances)



ChemID (*Plus Advanced*)

Substance	CAS number	Molecular structure	Structural similarity (%)	
1-Butanol, 3-methoxy-, 1- acetate	4435-53-4	H ₃ C O CH ₃	100	
3-Hydroxybutyl acetate	1851-86-1		76	
1-Butanol, 3-methoxy-3- methyl-, acetate	103429-90-9		70	
3-Methylpentyl acetate	35897-13-3	CH ₃ CH ₃ CH ₃	69	
Propionic acid, 2-methyl-, 3-methoxybutyl ester	72785-13-8		67	
1,3-Butanediol, 1,3- diacetate	1117-31-3	H ₃ C CH ₃	65	
Acetic acid, 3-chlorobutyl ester	2203-36-3		64	
Ethanol, 2-(1- methylethoxy)-, 1-acetate	19234-20-9	H ₃ C O CH ₃	63	
3-Methoxybutyl acrylate	2768-07-2		62	
2-Methoxypropyl-1-acetate	70657-70-4		62	
3-Hydroxy-1-methylpropyl acetate	75355-65-6	но снз снз	61	
sec-Butyl acetate	105-46-4	о сн ₃ сн ₃	60	

?

?

27 NT - ITS, Japan 09

H

Read across: qualitative and quantitative

Qualitative: categorial similar responses (mut, sens, irrit..)

Quantitative: finding surrogate 'DNEL' \rightarrow *next slide*



Quantitative read across:





29 NT - ITS, Japan 09

Quantitative read across:







Organization for Economic Co-operation and Development

"QSAR Application Toolbox"

-filling data gaps using available NT data-



31 NT - ITS, Japan 09



What is the key feature of the Toolbox ?

to <u>systematically group</u> chemicals according to the presence or modulation of a particular effect for all members of the category based on the presumption of a common chemical or toxicological mechanism or mode of action.

to quickly evaluate all members of a category for common toxicological behaviour or consistent trends among important regulatory endpoint data.





What tools are in the Toolbox ?

The Toolbox estimates missing values by:

- **Read-Across**, that extrapolates for an untested chemical from tested chemicals within a category
- **Trend Analysis**, that estimates for an untested chemical from a "trend" (increasing, decreasing or constant) in effect within a category
- (Q)SAR Models that estimate missing values from a statistical model for a category



Structure of the QSAR Toolbox

Logical sequence of components usage

Chemical input	Profiling	Endpoints	Category Definition	-	Report

Use of components via:

- "rigid tract"
- "flexible tract"



3. Our experience On identifying similar structures

- All tools appear to have different similarity algorithms
- Basis of similarity algorithms is obscure (for toxicologists)
- Similarity outcome appears not always toxicologically-funded
- Additional expert judgement is needed



3. Our experience OECD QSAR Toolbox

- User friendly (once familiar to its structure)
- Data very well organised
- Toxicological and chemistry expertise is required
- Reliability depends on structure complexity, data availability and experience user
- Transparency high (reporting module)
- At present limited to human health endpoints mutagenicity & sensitisation only


3. Our experience Using NT data

- One should start with concrete cases and apply available tools; to built capacity & expertise
- It is not be learned, like from a cookbook
- Toxicological and chemistry expertise needed (or hired)

How will ECHA respond, what will it accept??



4. Developments for generating NT data



The current situation on available testing data

for about 30.000 (?!) REACH chemicals > 1 tpa



Allanou, Hansen and van Der Bilt, 1999

The current situation on available testing data

Non-Testing data need Testing data!!

Existing data should be made (publicly) available!

New data should be generated in an intelligent way!



Toxicology Mechanisms and Methods, 18:103–118, 2008 Copyright © Informa Healthcare USA, Inc. ISSN: 1537-6516 print; 1537-6524 online DOI: 10.1080/15376510701857452

Existing data should be made (publicly) available!

REVIEW

informa

healthcare

Toxicity Data Informatics: Supporting a New Paradigm for Toxicity Prediction

Ann M. Richard

National Center for Computational Toxicology, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711 Chihae Yang

Leadscope, Inc., Columbus, OH 43235

Richard S. Judson

National Center for Computational Toxicology, U.S. Environmental Protection AgencyResearch Triangle Park, NC 27711



DSSTox databases: Concept



T

NAMEID	version #records date	Expanded DSSTox Data File Title & Description		
PDBAS	v5b 1547 10Feb2008	Carcinogenic Potency Database Summary Tables - All Species: Tumor target site incidence, TD50 potencies, summary activity calls for rat, mouse, hamster, dog, and/or non-human primate; data reviewed and compiled from literature and NTP studies.		
BPCAN	v4b 209 15Feb2008	EPA Water Disinfection By-Products with Carcinogenicity Estimates Database: Carcinogenicity estimates (high, moderate, low concern) by EPA experts using a mechanism-based analog SAR approach on a set of 209 water disinfection by-products, mostly small halogenated organics.		
PAFHM	v4b 617 15Feb2008	EPA Fathead Minnow Acute Toxicity Database: Acute toxicities of 617 chemicals tested in common assay, with mode-of-action assessments an confirmatory measures.		
DAMDD	v3b	EDA Center for Drug Evaluation & Research - Maximum (Recommended) Daily Dose Database: Maximum (recommende		
Î	1216 15Feb2008	DSSTox currently with 9 databases	s extracted from	
PVCSI	v2c 3548 15Feb2008	operational and accessable by internet for	d on EPA HPV	
IPVISD	v1b 1006 15Feb2008		chemical inventory o erties and toxicity	
<u>RISTR</u>	v1b 544 15Feb2008	identifying structural analogues and		
ICTRER	v4b 232 15Feb2008	retrieving associated toxicological profiles	binding affinities	
	v2b 2293 15Feb2008	National Toxicology Program (NTP) On-line Chemical Bioassay Database <u>Structure-Index Locator File</u> : Compiled structu Database with chemical-specific URLs linking to NTP study summary pages; file includes fields for each of 4 main bioassay indicator values specifying presence or absence of study data for the chemical substance record.		
ITPHTS	v2b 1408 15Feb2008	National Toxicology Program (NTP) High-Throughput Screening Project <u>Structure-Index File</u> : Compiled structures for set of substances provided to the NIH Chemical Genomics Center for HTS bioassay testing and to PubChem (PubChem_CIDs and included in NTPHTS_v2a file); NCGC HTS bioassay data are being deposited into PubChem and can be retrieved with the CID and SID record listings.	PubChem_SIDs	
OXCIST	v2b 320 08Feb2008	Research Chemical Inventory for EPA's ToxCast m Program <u>Structure-Index File</u> : Compiled structures for 320 chemical st candidates for Phase I High-Throughput screening (HTS) within the EPA ToxCastm program. File will be updated with links SIDs for retrieving assay data, and with updates to chemical inventory as Program moves to Phase II and beyond.		

New data should be generated in an intelligent way!

Strategy to efficiently fill 'inadequately filled' and 'empty' chemical categories (chemical domains) !!



Once a datagap is 'filled' with NT data....

is that information sufficient to replace Testing data??

or

How to 'weight' NT data

and

How to 'add' NT data to Testing data...?

By Expert judgement or more formalized WoE...?







5. Exposure-based Waiving (EBW)



General rules for adaptation of Standard Requirements

Annex XI

- 1. Testing does not appear scientifically necessary
 - Use of existing data: PC, non-GLP etc, Historical human data
 - Weight of evidence
 - In vitro methods
 - Quantitative or Qualitative Structure Activity Relationships ((Q)SAR)
 - Grouping of substances and read-across approach
- 2. Testing is technically not possible
- 3. Substance-tailored exposure-driven testing



ITS: Information Gathering Strategy

Step 1: Gather all available Testing and Non-Testing information

If not sufficient (for C&L and RA)

(Is Testing technically possible?)

Step 2: Is Exposure-Based Waiving an option?

If not possible

Step 3: Perform / Propose Testing as last resort!!



EBW: General rules Annex XI

Tonnage	Health Information requirements	
1 – 10 tpa	 <i>In vitro</i> skin and eye irritation Skin sensitization <i>In vitro</i> mutagenicity Acute toxicity (one route) 	
10 – 100 tpa	 In vivo skin and eye irritation Further <i>in vitro</i> mutagenicity Acute toxicity (2nd route) Sub acute toxicity (28d) Reproductive toxicity screen 	
100 – 1000 tpa	 Further mutagenicity tests Sub-chronic toxicity (90d)* Reproductive toxicity tests 	
>1000 tpa	 Further mutagenicity tests Chronic toxicity (>12 m)* may Further reproductive toxicity tests Carcinogenicity may 	

Tests may be omitted based on the exposure scenarios developed.

In all cases, adequate justification and documentation shall be provided of the exposure estimate derived.



50 NT - ITS, Japan 09

• Sub acute toxicity (28d) is available

EBW: Specific rules

Tonnage	Health Information requirements	Specific rules of adaptation 'on exposure' (column 2 of Annexes VIII-X)
1 – 10 tpa	 In vitro skin and eye irritation Skin sensitization In vitro mutagenicity Acute toxicity (one route) 	• None
10 – 100 tpa	 In vivo skin and eye irritation Further in vitro mutagenicity Acute toxicity (2nd route) Sub acute toxicity (28d) Reproductive toxicity screen 	 No NA No (route specifics) Relevant human exposure can be excluded<i>cf</i> Annex XI.3 Relevant human exposure can be excluded<i>cf</i> Annex XI.3
100 – 1000 tpa	 Further mutagenicity tests Sub-chronic toxicity (90d) * Reproductive toxicity tests 	 NA unreactive, insoluble, and not inhalable, and no evidence of absorption & toxicity, coupled with limited human exposure. low tox, and no systemic absorption, and no or no significant human exposure.
>1000 tpa	 Further mutagenicity tests Chronic toxicity (>12 m)* may Further reproductive toxicity tests Carcinogenicity may 	 NA low tox, and no systemic absorption, and no or no significant human exposure. NA

•^{*}Sub acute toxicity (28d) is available

51 NT - ITS, Japan 09



Guidance?

Presently under construction:

Qualitative approach & Quantitative approach Document by RIVM



EBW, qualitative approach

Situations for EBW	Explanation	
Specific use or limited emissions	Certain uses excluded: - no consumer exposure - no professional application Emissions to certain env compartments are excluded (e.g. air emissions irrelevant as substance is solid and forms no dust).	
Specific operational or use conditions	Use in (semi)closed systems, leading to limited or negligible exposure Use in strictly controlled systems with extensive PPE due to the toxicity of the substance	
Intensity of use (duration, frequency)	Infrequent use due to function of substance, e.g. specialty products for highly specific occupational situations with a low frequency and duration	
Substance properties	Phys-chem properties of preparation or article, e.g. when substance is locked in or covalently bound to matrix	



EBW, quantitative approach

When a qualitative justification is not preferred, not possible or not allowed:

A quantitative approach *cf* Annex XI can be submitted: adequate justification and documentation of waiving, based on an exposure assessment *cf* Annex I.5: description of development of an ES, and of the exposure estimation

This exposure estimate will be compared with a 'DNEL' or if this is not available it may be possible to use a TTC (Threshold of Toxicological Concern).

If this is not possible: additional hazard data need to be collected.



EBW, quantitative approach

```
If 'DNEL' or TTC available:
```

Risk Characterisation Ratio (RCR)



If RCR ≤ 1, then 'control of risk'; document and communicate in CSR and SDS+

If RCR > 1, then 'no control of risk' assessment needs to be refined



55 NT - ITS, Japan 09

REACH & TTC value

present situation

Based on route-specific database for food chemicals

route	workers	consumers	man-v-env
<mark>oral</mark> mg/kg bw,day		TTC	?
inhalation mg/m ³	?		?
dermal mg/kg bw,day; mg/cm²	?	?	?



REACH & 'DNEL' values

present situation

route	workers	consumers	man-v-env
oral mg/kg bw,day		'DNEL'	?
inhalation mg/m ³	?	, i	?
dermal mg/kg bw,day; mg/cm ²	?	?	?
NT - ITS, Japan 09			i.e. = 'chemical egory specific TTC'

57

What is 'significant' or 'relevant' exposure ?





REACH & TTC values

present situation

TTC for oral route:

- large database available (some identified exceptions)
- but coverage REACH substances domain unclear

TTC for inhalation and dermal routes urgently needed:

Preferably route-specific, but:

- number of useful studies limited, and consequently
- applicability to REACH substances domain limited

If obtained via appropriate route-to-route extrapolation:

- larger database, higher coverage REACH substances domain,
- but uncertainty on potential local effects

There is a need for tools to derive chemical category confined TTCs



EBW: promising.....?

Guidance on Qualitative approach & Quantitative approach under construction

3 EU SC developed an Opinion Document on TTC.. quite critical on this tool...

CIE recently published revised legal section 3 Annex XI: more stringent criteria...



5. Final Conclusions

Additional chemistry & toxicological expertise clearly is needed to generate and assess NT data.

The NT data area is a rapidly developing field: many new tools and options (note potential overlap when using more than one)

The QSAR Toolbox is helpful and user-friendly tool but critically dependent on more testdata input: DSSTox, ToxCast, Fraunhofer and a Japanese databases on complex human endpoints will be incorporated

EBW appears to become a difficult route.....



5. Final Conclusions (2)

There are no worked-out examples

How will ECHA respond to any NT approaches?

Will REACH be achievable, then a 'mind-set' is needed!



Thank you for your attention!

